18F-FDG PET/CT and urothelial carcinoma

Impact on management and prognosis—a multicenter retrospective study

Fabio Zattoni, Elena Incerti, Fabrizio Dal Moro, Marco Moschini, Paolo Castellucci, Stefano Panareo, Maria Picchio, Federico Fallanca, Alberto Briganti, Andrea Gallina, Stefano Fanti, Riccardo Schiavina, Eugenio Brunocilla, Ilaria Rambaldi, Val Lowe, Robert Jeffrey Karnes, Laura Evangelista

Research output: Contribution to journalArticle

Abstract

Objectives: To evaluate the ability of18F-labeled fluoro-2-deoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) to predict survivorship of patients with bladder cancer (BC) and/or upper urinary tract carcinoma (UUTC). Materials: Data from patients who underwent FDG PET/CT for suspicion of recurrent urothelial carcinoma (UC) between 2007 and 2015 were retrospectively collected in a multicenter study. Disease management after the introduction of FDG PET/CT in the diagnostic algorithm was assessed in all patients. Kaplan-Meier and log-rank analysis were computed for survival assessment. A Cox regression analysis was used to identify predictors of recurrence and death, for BC, UUTC, and concomitant BC and UUTC. Results: Data from 286 patients were collected. Of these, 212 had a history of BC, 38 of UUTC and 36 of concomitant BC and UUTC. Patient management was changed in 114/286 (40%) UC patients with the inclusion of FDG PET/CT, particularly in those with BC, reaching 74% (n = 90/122). After a mean follow-up period of 21 months (Interquartile range: 4–28 mo.), 136 patients (47.4%) had recurrence/progression of disease. Moreover, 131 subjects (45.6%) died. At Kaplan-Meier analyses, patients with BC and positive PET/CT had a worse overall survival than those with a negative scan (log-rank < 0.001). Furthermore, a negative PET/CT scan was associated with a lower recurrence rate than a positive examination, independently from the primary tumor site. At multivariate analysis, in patients with BC and UUTC, a positive FDG PET/CT resulted an independent predictor of disease-free and overall survival (p < 0,01). Conclusions: FDG PET/CT has the potential to change patient management, particularly for patients with BC. Furthermore, it can be considered a valid survival prediction tool after primary treatment in patients with recurrent UC. However, a firm recommendation cannot be made yet. Further prospective studies are necessary to confirm our findings.

Original languageEnglish (US)
Article number700
JournalCancers
Volume11
Issue number5
DOIs
StatePublished - May 1 2019

Fingerprint

Fluorodeoxyglucose F18
Multicenter Studies
Retrospective Studies
Urinary Bladder Neoplasms
Carcinoma
Urologic Neoplasms
Urinary Tract
Recurrence
Survival
Deoxyglucose
Kaplan-Meier Estimate
Disease Management
Disease-Free Survival
Disease Progression
Multivariate Analysis
Survival Rate
Regression Analysis
Prospective Studies

Keywords

  • Bladder cancer
  • PET/CT
  • Survival
  • Upper tract urothelial carcinoma
  • Urothelial carcinoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Zattoni, F., Incerti, E., Dal Moro, F., Moschini, M., Castellucci, P., Panareo, S., ... Evangelista, L. (2019). 18F-FDG PET/CT and urothelial carcinoma: Impact on management and prognosis—a multicenter retrospective study. Cancers, 11(5), [700]. https://doi.org/10.3390/cancers11050700

18F-FDG PET/CT and urothelial carcinoma : Impact on management and prognosis—a multicenter retrospective study. / Zattoni, Fabio; Incerti, Elena; Dal Moro, Fabrizio; Moschini, Marco; Castellucci, Paolo; Panareo, Stefano; Picchio, Maria; Fallanca, Federico; Briganti, Alberto; Gallina, Andrea; Fanti, Stefano; Schiavina, Riccardo; Brunocilla, Eugenio; Rambaldi, Ilaria; Lowe, Val; Karnes, Robert Jeffrey; Evangelista, Laura.

In: Cancers, Vol. 11, No. 5, 700, 01.05.2019.

Research output: Contribution to journalArticle

Zattoni, F, Incerti, E, Dal Moro, F, Moschini, M, Castellucci, P, Panareo, S, Picchio, M, Fallanca, F, Briganti, A, Gallina, A, Fanti, S, Schiavina, R, Brunocilla, E, Rambaldi, I, Lowe, V, Karnes, RJ & Evangelista, L 2019, '18F-FDG PET/CT and urothelial carcinoma: Impact on management and prognosis—a multicenter retrospective study', Cancers, vol. 11, no. 5, 700. https://doi.org/10.3390/cancers11050700
Zattoni F, Incerti E, Dal Moro F, Moschini M, Castellucci P, Panareo S et al. 18F-FDG PET/CT and urothelial carcinoma: Impact on management and prognosis—a multicenter retrospective study. Cancers. 2019 May 1;11(5). 700. https://doi.org/10.3390/cancers11050700
Zattoni, Fabio ; Incerti, Elena ; Dal Moro, Fabrizio ; Moschini, Marco ; Castellucci, Paolo ; Panareo, Stefano ; Picchio, Maria ; Fallanca, Federico ; Briganti, Alberto ; Gallina, Andrea ; Fanti, Stefano ; Schiavina, Riccardo ; Brunocilla, Eugenio ; Rambaldi, Ilaria ; Lowe, Val ; Karnes, Robert Jeffrey ; Evangelista, Laura. / 18F-FDG PET/CT and urothelial carcinoma : Impact on management and prognosis—a multicenter retrospective study. In: Cancers. 2019 ; Vol. 11, No. 5.
@article{78bde7b27dba4b9cbe745af2a5e822f8,
title = "18F-FDG PET/CT and urothelial carcinoma: Impact on management and prognosis—a multicenter retrospective study",
abstract = "Objectives: To evaluate the ability of18F-labeled fluoro-2-deoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) to predict survivorship of patients with bladder cancer (BC) and/or upper urinary tract carcinoma (UUTC). Materials: Data from patients who underwent FDG PET/CT for suspicion of recurrent urothelial carcinoma (UC) between 2007 and 2015 were retrospectively collected in a multicenter study. Disease management after the introduction of FDG PET/CT in the diagnostic algorithm was assessed in all patients. Kaplan-Meier and log-rank analysis were computed for survival assessment. A Cox regression analysis was used to identify predictors of recurrence and death, for BC, UUTC, and concomitant BC and UUTC. Results: Data from 286 patients were collected. Of these, 212 had a history of BC, 38 of UUTC and 36 of concomitant BC and UUTC. Patient management was changed in 114/286 (40{\%}) UC patients with the inclusion of FDG PET/CT, particularly in those with BC, reaching 74{\%} (n = 90/122). After a mean follow-up period of 21 months (Interquartile range: 4–28 mo.), 136 patients (47.4{\%}) had recurrence/progression of disease. Moreover, 131 subjects (45.6{\%}) died. At Kaplan-Meier analyses, patients with BC and positive PET/CT had a worse overall survival than those with a negative scan (log-rank < 0.001). Furthermore, a negative PET/CT scan was associated with a lower recurrence rate than a positive examination, independently from the primary tumor site. At multivariate analysis, in patients with BC and UUTC, a positive FDG PET/CT resulted an independent predictor of disease-free and overall survival (p < 0,01). Conclusions: FDG PET/CT has the potential to change patient management, particularly for patients with BC. Furthermore, it can be considered a valid survival prediction tool after primary treatment in patients with recurrent UC. However, a firm recommendation cannot be made yet. Further prospective studies are necessary to confirm our findings.",
keywords = "Bladder cancer, PET/CT, Survival, Upper tract urothelial carcinoma, Urothelial carcinoma",
author = "Fabio Zattoni and Elena Incerti and {Dal Moro}, Fabrizio and Marco Moschini and Paolo Castellucci and Stefano Panareo and Maria Picchio and Federico Fallanca and Alberto Briganti and Andrea Gallina and Stefano Fanti and Riccardo Schiavina and Eugenio Brunocilla and Ilaria Rambaldi and Val Lowe and Karnes, {Robert Jeffrey} and Laura Evangelista",
year = "2019",
month = "5",
day = "1",
doi = "10.3390/cancers11050700",
language = "English (US)",
volume = "11",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "5",

}

TY - JOUR

T1 - 18F-FDG PET/CT and urothelial carcinoma

T2 - Impact on management and prognosis—a multicenter retrospective study

AU - Zattoni, Fabio

AU - Incerti, Elena

AU - Dal Moro, Fabrizio

AU - Moschini, Marco

AU - Castellucci, Paolo

AU - Panareo, Stefano

AU - Picchio, Maria

AU - Fallanca, Federico

AU - Briganti, Alberto

AU - Gallina, Andrea

AU - Fanti, Stefano

AU - Schiavina, Riccardo

AU - Brunocilla, Eugenio

AU - Rambaldi, Ilaria

AU - Lowe, Val

AU - Karnes, Robert Jeffrey

AU - Evangelista, Laura

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Objectives: To evaluate the ability of18F-labeled fluoro-2-deoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) to predict survivorship of patients with bladder cancer (BC) and/or upper urinary tract carcinoma (UUTC). Materials: Data from patients who underwent FDG PET/CT for suspicion of recurrent urothelial carcinoma (UC) between 2007 and 2015 were retrospectively collected in a multicenter study. Disease management after the introduction of FDG PET/CT in the diagnostic algorithm was assessed in all patients. Kaplan-Meier and log-rank analysis were computed for survival assessment. A Cox regression analysis was used to identify predictors of recurrence and death, for BC, UUTC, and concomitant BC and UUTC. Results: Data from 286 patients were collected. Of these, 212 had a history of BC, 38 of UUTC and 36 of concomitant BC and UUTC. Patient management was changed in 114/286 (40%) UC patients with the inclusion of FDG PET/CT, particularly in those with BC, reaching 74% (n = 90/122). After a mean follow-up period of 21 months (Interquartile range: 4–28 mo.), 136 patients (47.4%) had recurrence/progression of disease. Moreover, 131 subjects (45.6%) died. At Kaplan-Meier analyses, patients with BC and positive PET/CT had a worse overall survival than those with a negative scan (log-rank < 0.001). Furthermore, a negative PET/CT scan was associated with a lower recurrence rate than a positive examination, independently from the primary tumor site. At multivariate analysis, in patients with BC and UUTC, a positive FDG PET/CT resulted an independent predictor of disease-free and overall survival (p < 0,01). Conclusions: FDG PET/CT has the potential to change patient management, particularly for patients with BC. Furthermore, it can be considered a valid survival prediction tool after primary treatment in patients with recurrent UC. However, a firm recommendation cannot be made yet. Further prospective studies are necessary to confirm our findings.

AB - Objectives: To evaluate the ability of18F-labeled fluoro-2-deoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) to predict survivorship of patients with bladder cancer (BC) and/or upper urinary tract carcinoma (UUTC). Materials: Data from patients who underwent FDG PET/CT for suspicion of recurrent urothelial carcinoma (UC) between 2007 and 2015 were retrospectively collected in a multicenter study. Disease management after the introduction of FDG PET/CT in the diagnostic algorithm was assessed in all patients. Kaplan-Meier and log-rank analysis were computed for survival assessment. A Cox regression analysis was used to identify predictors of recurrence and death, for BC, UUTC, and concomitant BC and UUTC. Results: Data from 286 patients were collected. Of these, 212 had a history of BC, 38 of UUTC and 36 of concomitant BC and UUTC. Patient management was changed in 114/286 (40%) UC patients with the inclusion of FDG PET/CT, particularly in those with BC, reaching 74% (n = 90/122). After a mean follow-up period of 21 months (Interquartile range: 4–28 mo.), 136 patients (47.4%) had recurrence/progression of disease. Moreover, 131 subjects (45.6%) died. At Kaplan-Meier analyses, patients with BC and positive PET/CT had a worse overall survival than those with a negative scan (log-rank < 0.001). Furthermore, a negative PET/CT scan was associated with a lower recurrence rate than a positive examination, independently from the primary tumor site. At multivariate analysis, in patients with BC and UUTC, a positive FDG PET/CT resulted an independent predictor of disease-free and overall survival (p < 0,01). Conclusions: FDG PET/CT has the potential to change patient management, particularly for patients with BC. Furthermore, it can be considered a valid survival prediction tool after primary treatment in patients with recurrent UC. However, a firm recommendation cannot be made yet. Further prospective studies are necessary to confirm our findings.

KW - Bladder cancer

KW - PET/CT

KW - Survival

KW - Upper tract urothelial carcinoma

KW - Urothelial carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85066949698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066949698&partnerID=8YFLogxK

U2 - 10.3390/cancers11050700

DO - 10.3390/cancers11050700

M3 - Article

VL - 11

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 5

M1 - 700

ER -